It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Few histological prognostic indicators for end-stage renal disease (ESRD) have been validated in diabetic patients. This biopsy-based study aimed to identify nephropathological risk factors for ESRD in Chinese patients with type 2 diabetes. Histological features of 322 Chinese type 2 diabetic patients with biopsy-confirmed diabetic nephropathy (DN) were retrospectively analysed. Cox proportional hazards analysis was used to estimate the hazard ratio (HR) for ESRD. Single glomerular proteomics and immunohistochemistry were used to identify differentially expressed proteins and enriched pathways in glomeruli. During the median follow-up period of 24 months, 144 (45%) patients progressed to ESRD. In multivariable models, the Renal Pathology Society classification failed to predict ESRD, although the solidified glomerulosclerosis (score 1: HR 1.65, 95% confidence interval [CI] 1.04–2.60; score 2: HR 2.48, 95% CI 1.40–4.37) and extracapillary hypercellularity (HR 2.68, 95% CI 1.55–4.62) were identified as independent risk factors. Additionally, single glomerular proteomics, combined with immunohistochemistry, revealed that complement C9 and apolipoprotein E were highly expressed in solidified glomerulosclerosis. Therefore, solidified glomerulosclerosis and extracapillary hypercellularity predict diabetic ESRD in Chinese patients. Single glomerular proteomics identified solidified glomerulosclerosis as a unique pathological change that may be associated with complement overactivation and abnormal lipid metabolism.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 West China Hospital of Sichuan University, Division of Nephrology, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022)
2 West China Hospital of Sichuan University, Division of Pathology, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022)
3 West China Hospital/ West China School of Medicine of Sichuan University, West China Biomedical Big Data Center, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022)
4 West China Hospital of Sichuan University, Key Laboratory of Transplant Engineering and Immunology, Ministry of Health, Regenerative Medicine Research Center, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022); West China Hospital of Sichuan University, West China-Washington Mitochondria and Metabolism Research Center, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022)
5 West China Hospital of Sichuan University, West China-Washington Mitochondria and Metabolism Research Center, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022)
6 West China Hospital of Sichuan University, Key Laboratory of Transplant Engineering and Immunology, Ministry of Health, Regenerative Medicine Research Center, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022)
7 West China Hospital of Sichuan University, Division of Endocrinology, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022)
8 Baylor University Medical Center at Dallas, Department of Pathology, Dallas, USA (GRID:grid.411588.1) (ISNI:0000 0001 2167 9807)
9 Monash University, Department of Diabetes, Central Clinical School, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)